美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

美國抗疫概念

1,467.14

-3.0465-0.21%

漲家數：10

跌家數：10

平家數：- -

市盈率：- -

高：1,469.90

開：1,469.76

低：1,454.86

收：1,470.19

資料載入中...

BUZZ-Novavax 季度虧損收窄後上漲

印度工廠進口受限，製藥商 Viatris 預計 2025 年業績疲軟

諾維信縮減 COVID 疫苗支出，季度虧損減少

BUZZ-Moderna 在報導特朗普政府考慮取消對其禽流感疫苗的資助後下跌

一代分子POCT明星落幕！

股息股陷入困境，如何在風雲變幻的市場中穩健獲利？

新藥開發難，輝瑞、渤健接連削減研發管線！

中国制药网

阿斯利康(AZN.US)口服小分子療法3期臨牀試驗結果積極

加密市場板塊部分反彈，BTC和ETH仍未止跌

康方生物合作伙伴summit與輝瑞探究聯合療法，賦能AK112全球臨牀

維爾生物技術公司公佈截至 12 月 31 日的季度業績 - 收益摘要

據彭博新聞社報道，特朗普政府正在權衡撤銷對 Moderna 禽流感疫苗的資助

Corvus Pharmaceuticals, Inc.盤中異動大幅拉昇5.52%報4.16美元

【歐股“十一羅漢”｜阿斯麥和LVMH集團收漲超2%，諾和諾德跌超2%】週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲2.39%，報714.50歐元。諾和諾德哥本哈根股價收跌2.16%，報642.80。LVMH集團漲2.35%，德國思愛普Sap漲1.03%，歐萊雅、賽諾菲、羅氏製藥漲0.81%-0.20%。阿斯利康則收跌0.42%，葛蘭素史克和雀巢至多跌2.16%，諾華製藥跌3.85%。

阿斯利康斥資併購羅沙司他在華所有權利

经济参考报

Equillium, Inc.盤中異動快速跳水5.78%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1467.1393,"timestamp":1741294799999,"preClose":1470.1858,"halted":0,"volume":105471886,"delay":0,"changeRate":-0.002072,"change":-3.046509,"pbRate":4.026038,"amount":5675719740.654533,"amplitude":0.01023,"prevYearClose":1274.8187,"fiveDayClose":1446.7607,"twentyDayClose":1373.9138,"turnoverRate":0.00682,"marketCap":1210199793589.5,"floatMarketCap":1188113526137,"peRate":31.895692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1469.9016,"amplitude":0.01023,"preClose":1470.1858,"low":1454.8619,"pbRate":"4.026038","latestPrice":1467.1393,"volume":105471886,"delay":0,"open":1469.7611,"prevYearClose":1274.8187,"prevWeekClose":1463.5875,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1446.7607,"twentyDayClose":1373.9138,"sixtyDayClose":1299.5834,"secType":"PLATE","market":"US","turnoverRate":0.00682,"peRate":31.895692,"marketCap":1210199793589.5,"floatMarketCap":1188113526137,"timestamp":1741294799999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514280042","title":"BUZZ-Novavax 季度虧損收窄後上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2514280042","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514280042?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 22:04","pubTimestamp":1740665073,"startTime":"0","endTime":"0","summary":"2月27日 -  ** 总部位于马里兰州的疫苗生产商 Novavax NVAX.O 股价盘前上涨 1.6%，报 7.44 美元 ** 该公司公布  第四季度每股亏损 51 美分，去年同期  每股 亏损 1.44 美元，原因是该公司减少了 COVID 疫苗的支出。** COVID 疫苗的季度销售额为 4,980 万美元，同比下降 80.2 ** NVAX 在过去 12 个月中上涨了 33(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3S3PI1BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","NVAX","BK4139","BK4547","BK4568"],"gpt_icon":0},{"id":"2514780287","title":"印度工廠進口受限，製藥商 Viatris 預計 2025 年業績疲軟","url":"https://stock-news.laohu8.com/highlight/detail?id=2514780287","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514780287?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 21:18","pubTimestamp":1740662318,"startTime":"0","endTime":"0","summary":"Viatris 的股票在盘前交易中下跌了 14.6%。Viatris于2024年12月23日披露，由于违反联邦要求，美国食品和药物管理局 已限制  从其位于印度印多尔 的工厂进口 11种产品。根据 LSEG 编制的数据，总部位于宾夕法尼亚州卡农斯堡的Viatris 预计 2025 年收入在 135 亿美元 至 140  亿美元之间，低于分析师预计的 142.7 亿美元。由于担心产品短缺，美国食品和药物管理局已允许 Viatris 的四种产品例外，但具体产品尚未披露。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3T3PI18P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999011175.SGD","LU0868494617.USD","LU0306806265.USD","SG9999001176.USD","LU0985481810.HKD","LU1066053197.SGD","SG9999002232.USD","IE00B19Z3581.USD","LU1894683348.USD","VTRS","LU1839511570.USD","LU0289739699.SGD","BK4581","SG9999003800.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU2087621335.USD","IE00BBT3K403.USD","LU0225771236.USD","BK4585","LU1883839398.USD","LU0456855351.SGD","BK4583","BK4568","LU0306807586.USD","LU0058720904.USD","SG9999001176.SGD","BK4007","IE000M9KFDE8.USD","LU1066051498.USD","LU0321505439.SGD","LU0225284248.USD","SG9999002224.SGD","BK4588","BK4592","IE00BLSP4452.SGD","LU0170899867.USD","LU0122379950.USD","LU0234572021.USD","LU1894683264.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","IE00BLSP4239.USD","BK4599","BK4550","BK4534","LU1057294990.SGD","BK4533"],"gpt_icon":1},{"id":"2514048588","title":"諾維信縮減 COVID 疫苗支出，季度虧損減少","url":"https://stock-news.laohu8.com/highlight/detail?id=2514048588","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514048588?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 21:02","pubTimestamp":1740661358,"startTime":"0","endTime":"0","summary":"路透社2月27日 - 周四，NovavaxNVAX.O第四季度亏损收窄，原因是其唯一上市产品COVID-19疫苗的销售和管理费用减少。Novavax报告称，COVID疫苗的季度销售额为4980万美元，同比下降了80.2%。该公司将依靠与赛诺菲的交易和在研疫苗带来的收入，包括处于临床前阶段的试验性 COVID 流感复合疫苗和禽流感疫苗。诺瓦维克斯表示，它有资格从赛诺菲的销售额中获得百分之十几到二十几的特许权使用费，以及与 COVID 流感组合产品相关的 3.5 亿美元的商业投放费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3T3PI17I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU0456855351.SGD","LU1883839398.USD","LU0868494617.USD","LU0122379950.USD","BK4568","LU0170899867.USD","LU1066051498.USD","BK4551","LU0321505439.SGD","LU1894683348.USD","SG9999002224.SGD","SG9999001176.SGD","BK4581","SG9999003800.SGD","BK4548","SGXZ57979304.SGD","BK4501","BK4550","BK4585","LU0225771236.USD","SG9999013999.USD","BK4534","BK4532","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0985481810.HKD","BK4547","IE000M9KFDE8.USD","BK4592","IE00BBT3K403.USD","LU0058720904.USD","IE00BLSP4452.SGD","NVAX","LU0306807586.USD","LU0234572021.USD","LU1023059063.AUD","LU0306806265.USD","BK4588","BK4007","BK4139","LU1066053197.SGD","LU1894683264.USD","SG9999001176.USD","BK4533","BK4599","IE00BLSP4239.USD","LU0321505868.SGD"],"gpt_icon":1},{"id":"2514874343","title":"BUZZ-Moderna 在報導特朗普政府考慮取消對其禽流感疫苗的資助後下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2514874343","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514874343?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 18:32","pubTimestamp":1740652365,"startTime":"0","endTime":"0","summary":"** 美国政府今年 1 月向  MRNA 公司拨款 5.9 亿美元，用于推进其禽流感疫苗的开发。** 股价在过去 12 个月中下跌了近 65(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3T3PI0W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4501","BK4533","BK4534","BK4551","BK4585","MRNA","BK4139","BK4548","BK4568"],"gpt_icon":1},{"id":"2514388535","title":"一代分子POCT明星落幕！","url":"https://stock-news.laohu8.com/highlight/detail?id=2514388535","media":"IVD资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514388535?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:50","pubTimestamp":1740649837,"startTime":"0","endTime":"0","summary":"Lucira Health从破产到收购2023年2月22日，美国明星分子诊断公司Lucira Health因财务压力向特拉华州破产法院申请破产保护。Lucira的破产反映POCT领域竞争激烈，技术门槛与商业化能力缺一不可。Lucira的分子POCT虽具创新性，但成本与供应链问题导致盈利困难；新冠检测退潮后，企业转向多元检测场景，并拓展基层医疗与家庭市场，但未能成功突破。辉瑞看中Lucira的分子POCT技术及FDA获批产品线，认为其资源可推动后续商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227220810abdf6864&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227220810abdf6864&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PFE","LU1057294990.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1023059063.AUD","SGXZ57979304.SGD","BK4585","BK4533","LU0170899867.USD","LU0868494617.USD","LU0122379950.USD","IE0002270589.USD","LU0306806265.USD","IE00B19Z3B42.SGD","SG9999013999.USD","BK4581","LU0225771236.USD","LU1066053197.SGD","LU0058720904.USD","SG9999002232.USD","LU1894683264.USD","LU0289739699.SGD","BK4568","LU0985481810.HKD","SG9999001176.USD","IE00BBT3K403.USD","LU1066051498.USD","BK4592","BK4588","IE00BLSP4452.SGD","SG9999002224.SGD","BK4534","SG9999003800.SGD","LU0306807586.USD","BK4599","LU0234572021.USD","LU0456855351.SGD","LU0321505868.SGD","SG9999011175.SGD","LU1883839398.USD","IE00BLSP4239.USD","LU0225284248.USD","SG9999001176.SGD","POCT","LU1894683348.USD","IE00B19Z3581.USD","BK4550"],"gpt_icon":1},{"id":"2514820512","title":"股息股陷入困境，如何在風雲變幻的市場中穩健獲利？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514820512","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514820512?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 16:35","pubTimestamp":1740645357,"startTime":"0","endTime":"0","summary":"近期股市波动加剧，股息股票不再是昔日的避风港，投资者该如何在这个不确定的市场中找到安全与收益？","market":"hk","thumbnail":"https://img.jin10.com/news/25/01/3KerOPN0Y4ZCCbt3yYMq7.png/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/news/25/01/3KerOPN0Y4ZCCbt3yYMq7.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=165057&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["LU1691799644.USD","BK4550","LU2112291526.USD","BK4533","BK4081","MMM","LU1057294990.SGD","LU1621768206.USD","LU2237957902.USD","T","LU2362541513.USD","LU0683600562.USD","LU1571399168.USD","LU2237957811.SGD","SGXZ23171101.USD","IE00BMG7P587.USD","BK4512","DOW","LU1989763690.USD","LU1023059063.AUD","LU1093756168.USD","BK4581","ABT","EIX","LU2089984988.USD","SG9999004303.SGD","LU0234572021.USD","BK4534","LU1621767737.EUR","IE00BMG7P694.USD","SG9999002232.USD","LU0868494617.USD","IE00BMG7P926.USD","LU0122379950.USD","LU1894683264.USD","BK4082","IE00B2B36J28.USD","LU1093756325.SGD","BK4568","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU2133065610.SGD","LU2449327464.USD","IE0009355771.USD","IE00BMG7P819.SGD","LU1621768115.EUR","BK4515","BK4206","BK4592","LU1061106388.HKD"],"gpt_icon":0},{"id":"2514842990","title":"新藥開發難，輝瑞、渤健接連削減研發管線！","url":"https://stock-news.laohu8.com/highlight/detail?id=2514842990","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514842990?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 14:04","pubTimestamp":1740636261,"startTime":"0","endTime":"0","summary":"近期，辉瑞、渤健、礼来等跨国制药巨头就已相继终止了多款高价新药的开发。近日，有报道称，辉瑞在宣布将终止B型血友病基因疗法Beqvez的开发和商业化。据悉，放弃Beqvez后，辉瑞打算将其资源集中在其认为将对患者产生重大影响的治疗方法上，例如近期获得批准的一种血友病A新药Hympavzi上。业内表示，这些药企终止药物开发的案例，反映出药企在新药开发和商业化上一直都在面临重大挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227141109a255d6e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227141109a255d6e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999011175.SGD","LU1894683348.USD","BK4007","BK4534","LU0234572021.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4585","LU1066051498.USD","LU1894683264.USD","LU0058720904.USD","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","BK4533","BK4568","BK4581","LU1057294990.SGD","BK4550","PFE","SG9999002232.USD","SG9999001176.SGD","LU1023059063.AUD","SG9999001176.USD","LU1066053197.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4592","LU0225771236.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999002224.SGD","IE00BLSP4239.USD","BK4588","LU0122379950.USD","IE00BLSP4452.SGD","LU0170899867.USD","LU0225284248.USD","LU0306807586.USD","LU0321505868.SGD","IE0002270589.USD","BK4599","LU1883839398.USD","IE00B19Z3B42.SGD","LU0985481810.HKD"],"gpt_icon":0},{"id":"2514593844","title":"阿斯利康(AZN.US)口服小分子療法3期臨牀試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2514593844","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514593844?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 14:01","pubTimestamp":1740636060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月27日，阿斯利康宣布，3期临床试验SERENA-6的中期分析显示，其在研口服选择性雌激素受体降解剂camizestrant与CDK4/6抑制剂联用，在主要终点无进展生存期上显示出统计学显著且具有临床意义的改善。据了解，SERENA-6是首个采用循环肿瘤DNA检测，发现肿瘤内分泌耐药性的出现并在疾病进展前提示治疗转换的全球性3期临床试验。Camizestrant是一种效力强劲的新一代口服SERD及雌激素受体完全拮抗剂，目前正在3期试验中接受评估，用于治疗HR阳性乳腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","LU0320765992.SGD","LU2456880835.USD","BK4007","BK4585","LU0889565916.HKD","LU1829250122.USD","LU2462157665.USD","LU2236285917.USD","BK1141","BK4588","BK1576","BK4568","03347","LU2417539215.USD","AZN","BK1583"],"gpt_icon":0},{"id":"2514810875","title":"加密市場板塊部分反彈，BTC和ETH仍未止跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2514810875","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514810875?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 11:24","pubTimestamp":1740626685,"startTime":"0","endTime":"0","summary":"Odaily星球日报讯 根据 SoSoValue 数据，加密市场板块部分反弹，但 Bitcoin （BTC）和 Ethereum （ETH）仍未止跌，24 小时分别下跌 4.24%、5.13%。值得注意的是，今日恐慌与贪婪指数降至 10，创 2022 年 6 月以来新低，市场整体陷入恐慌状态。\n此外，AI Agents 连续两日上涨，过去 24 小时涨幅为 4.04%；Layer2 板块上涨 2.76%，其中，Celestia（TIA）上涨 8.30%，Optimism（OP）上涨 11.63%。\n其他板块方面，AI 板块 24 小时上涨 2.14%，板块内 KAITO 上涨 43.22%；Layer1 板块上涨 1.13%，其中，Aptos（APT）、Story（IP）、Berachain（BERA）分别上涨 9.73%、22.89%、9.15%；DeFi 板块上涨 0.32%，Meme 板块下跌 0.11%，CeFi 板块下跌 2.05%，PayFi 板块下跌 2.77%。\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/newsflash/420927?source=share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["BK4594","BTC.USD.CC","OP.USD.HKCC","BTCmain","BK4086","09046","ETHV","LU2463526074.USD","FETH","ETH.USD.CC","BK4021","OP","BK1611","ETH","XBTmain","APT","LU1487256676.USD","APT.USD.CC","09008","BK4601","IP","09042","BK4585","09439","EZET","IBIT","BK4588","03009","83042","ETH.USD.HKCC","CETH","BK4568","BTC","QETH","APT.USD.HKCC","BK4136","03042","03008","BTC.USD.HKCC","LDO.USD.HKCC","09009","LU1481600234.SGD","09179","03179","LU1481599808.USD","03046","03439"],"gpt_icon":0},{"id":"2514818809","title":"康方生物合作伙伴summit與輝瑞探究聯合療法，賦能AK112全球臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2514818809","media":"中信建投","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514818809?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 08:16","pubTimestamp":1740615369,"startTime":"0","endTime":"0","summary":"事件康方生物/Su mmit AK112与辉瑞A DC探索联合疗法2025年2月24日，康方全球合作伙伴Su mmit Therapeutics宣布与辉瑞开展临床合作，以评估PD-1/VEGF双特异性抗体Ivonescimab与辉瑞的多种抗体偶联药物联合用于多种实体瘤的疗效和安全性。简评一、合作伙伴Su mmit与辉瑞达成合作，赋能AK112全球临床研发2025年2月24日，Su mmit Therapeutics公布2024年财报，披露了研发管线最新进展，同时宣布与辉瑞达成临床合作，开展PD-1/VEGF+A DC联合治疗实体瘤的临床探索。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227084028a2557e18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227084028a2557e18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0225284248.USD","LU0456855351.SGD","LU1883839398.USD","LU0868494617.USD","LU0122379950.USD","BK4568","LU0170899867.USD","LU1066051498.USD","LU0321505439.SGD","LU1894683348.USD","SG9999002224.SGD","SG9999001176.SGD","BK4581","SG9999003800.SGD","SGXZ57979304.SGD","BK4550","IE00B19Z3581.USD","BK4585","LU0225771236.USD","PFE","LU1057294990.SGD","SG9999013999.USD","BK4534","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0985481810.HKD","IE000M9KFDE8.USD","BK4592","IE00BBT3K403.USD","LU0058720904.USD","SG9999002232.USD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0306807586.USD","LU0234572021.USD","LU1023059063.AUD","LU0306806265.USD","BK4588","BK4007","SG9999001176.USD","LU1066053197.SGD","LU1894683264.USD","BK4533","BK4599","IE0002270589.USD","IE00BLSP4239.USD","LU0321505868.SGD"],"gpt_icon":1},{"id":"2514894195","title":"維爾生物技術公司公佈截至 12 月 31 日的季度業績 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2514894195","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514894195?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 07:31","pubTimestamp":1740612705,"startTime":"0","endTime":"0","summary":"维尔生物技术公司公布截至 12 月 31 日的季度业绩 - 收益摘要Vir Biotechnology Inc VIR.OQ报告，截至12月31日的季度调整后每股亏损76美分，高于去年同期的每股-86美分。Vir 生物技术公司公布的本季度每股收益为亏损 76 美分。该公司当季亏损1.0459亿美元。Vir Biotechnology Inc 的股价本季度上涨了 24.0%。生物技术和医学研究同行的平均一致建议也是 \"买入\"。华尔街对 Vir 生物技术公司 12 个月目标价的中位数为 20.00 美元。本摘要由 LSEG 2 月 26 日 11:31 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL3S3PH29E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4139","BK4585","BK4535","BK4568"],"gpt_icon":0},{"id":"2514601899","title":"據彭博新聞社報道，特朗普政府正在權衡撤銷對 Moderna 禽流感疫苗的資助","url":"https://stock-news.laohu8.com/highlight/detail?id=2514601899","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514601899?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 06:45","pubTimestamp":1740609940,"startTime":"0","endTime":"0","summary":"据彭博新闻社报道，特朗普政府正在权衡撤销对 Moderna 禽流感疫苗的资助路透社2月26日 - 彭博新闻社周三援引知情人士的话报道说，美国卫生官员正在重新评估授予Moderna MRNA.O的一份价值5.9亿美元的禽流感疫苗合同。 美国政府今年1月授予Moderna公司5.9亿美元，用于推进其禽流感疫苗的开发。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL3S3PH24T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4534","BK4501","BK4568","BK4585","BK4551","BK4139","BK4588","BK4533","BK4548","MRNA"],"gpt_icon":0},{"id":"2514862265","title":"Corvus Pharmaceuticals, Inc.盤中異動 大幅拉昇5.52%報4.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514862265?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 04:28","pubTimestamp":1740601714,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时28分，Corvus Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.52%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.69%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Salarius Pharmaceuticals, Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6844.95%、332.32%、265.02%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为194.07%、81.11%、70.39%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270428359893eace&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270428359893eace&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","CRVS","BK4139"],"gpt_icon":0},{"id":"2514695998","title":"【歐股“十一羅漢”｜阿斯麥和LVMH集團收漲超2%，諾和諾德跌超2%】週三，阿斯麥控股荷蘭阿姆斯特丹股價收漲2.39%，報714.50歐元。諾和諾德哥本哈根股價收跌2.16%，報642.80。LVMH集團漲2.35%，德國思愛普Sap漲1.03%，歐萊雅、賽諾菲、羅氏製藥漲0.81%-0.20%。阿斯利康則收跌0.42%，葛蘭素史克和雀巢至多跌2.16%，諾華製藥跌3.85%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514695998","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514695998?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 02:33","pubTimestamp":1740594799,"startTime":"0","endTime":"0","summary":"周三，阿斯麦控股荷兰阿姆斯特丹股价收涨2.39%，报714.50欧元。诺和诺德哥本哈根股价收跌2.16%，报642.80。LVMH集团涨2.35%，德国思爱普Sap涨1.03%，欧莱雅、赛诺菲、罗氏制药涨0.81%-0.20%。阿斯利康则收跌0.42%，葛兰素史克和雀巢至多跌2.16%，诺华制药跌3.85%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27023348414142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NSRGY","LU2417539215.USD","LU2456880835.USD","IE0002141913.USD","IE00BZ1G4Q59.USD","BK4543","IE00BD6J9T35.USD","LU1093756168.USD","LRLCY","IE0004445239.USD","BK4147","NVO","IE00BJT1NW94.SGD","LU2462157665.USD","BK4585","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","ASML","BK1191","LU1734074674.USD","BK4568","IE0009355771.USD","LU1093756325.SGD","LU2236285917.USD","01477","BK1574","BK4007","LU0823434583.USD","LU0109394709.USD","BK4212","AZN","NVS","LU0320765992.SGD","BK4183","GSK","BK4588","03165","LU0097036916.USD","BK4532","LU0154236417.USD","LU0823434740.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","LU1829250122.USD","LU0889565916.HKD","BK4599","GSK.UK"],"gpt_icon":0},{"id":"2514866400","title":"阿斯利康斥資併購羅沙司他在華所有權利","url":"https://stock-news.laohu8.com/highlight/detail?id=2514866400","media":"经济参考报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514866400?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 02:13","pubTimestamp":1740593625,"startTime":"0","endTime":"0","summary":"近日，阿斯利康与珐博进有限公司（简称“珐博进”）达成协议，将以约1.6亿美元（约合人民币12亿元）收购珐博进中国，拿下罗沙司他在中国的所有权利。有业内人士向《经济参考报》记者表示，作为全球医药巨头的阿斯利康并购中国公司，显示其代表行业及跨国公司持续看好中国发展机遇，也向市场传递了一个明确信号，即中国本土的生物科技和制药企业仍具备巨大的成长与投资潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502273330668420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273330668420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN","LU2462157665.USD","BK4007","BK4585","LU0889565916.HKD","BK4568","LU0320765992.SGD","BK4588","LU2456880835.USD","LU2236285917.USD","LU2417539215.USD","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2514866643","title":"Equillium, Inc.盤中異動 快速跳水5.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514866643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514866643?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 02:07","pubTimestamp":1740593254,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时07分，Equillium, Inc.股票出现异动，股价急速下跌5.78%。Equillium, Inc.股票所在的生物技术行业中，整体跌幅为0.39%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6400.71%、261.96%、239.71%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Pds Biotechnology Corporation，振幅分别为194.07%、49.18%、44.44%。Equillium, Inc.公司简介：Equillium Inc 是一家开发治疗自身免疫和炎症疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227020734a255286e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227020734a255286e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EQ","BK4568","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":10,"pageCount":6,"totalSize":158}]}}